全文获取类型
收费全文 | 949篇 |
免费 | 73篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 59篇 |
妇产科学 | 9篇 |
基础医学 | 89篇 |
口腔科学 | 29篇 |
临床医学 | 163篇 |
内科学 | 212篇 |
皮肤病学 | 12篇 |
神经病学 | 26篇 |
特种医学 | 241篇 |
外科学 | 61篇 |
综合类 | 21篇 |
预防医学 | 30篇 |
眼科学 | 7篇 |
药学 | 33篇 |
中国医学 | 5篇 |
肿瘤学 | 29篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 22篇 |
2017年 | 11篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 25篇 |
2013年 | 22篇 |
2012年 | 15篇 |
2011年 | 16篇 |
2010年 | 35篇 |
2009年 | 57篇 |
2008年 | 28篇 |
2007年 | 10篇 |
2006年 | 15篇 |
2005年 | 6篇 |
2004年 | 9篇 |
2003年 | 21篇 |
2002年 | 17篇 |
2001年 | 19篇 |
2000年 | 11篇 |
1999年 | 14篇 |
1998年 | 50篇 |
1997年 | 52篇 |
1996年 | 66篇 |
1995年 | 48篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 14篇 |
1991年 | 7篇 |
1990年 | 14篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 9篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1029条查询结果,搜索用时 167 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
10.
Seven DNA polymorphisms in the LDL receptor gene: application to the study of familial hypercholesterolemia in Spain 总被引:1,自引:0,他引:1
F. Javier Chaves Oscar Puig Magdalena Garcia-Sogo José Real José V. Gil Juan Ascaso Rafael Carmena M. Eugenia Armengod 《Clinical genetics》1996,50(1):28-35
We have performed restriction fragment length polymorphism (RFLP) analysis at the low density lipoprotein receptor (LDLR) locus in order to investigate the molecular genetics of familial hypercholesterolemia (FH) in Spain. Firstly, a sample of 50 unrelated patients with a clinical diagnosis of FH was screened for the presence of major rearrangements at this locus by Southern blot analysis of Bgt II digested genomic DNA. Four different mutations were detected, accounting for 8% of the mutant alleles in the Spanish FH sample. Then, we determined the relative allele frequency and estimated linkage disequilibrium between seven RFLPs of the LDLR gene in the remaining 46 FH patients and in 61 normolipidemic controls. Hindi, Avail, Pvu II, Msp I, and Nco I are the most polymorphic sites with individual PIC values higher than 0.28, whereas the Taq I and Stu I sites display low levels of polymorphism. The usefulness of the seven RFLPs to confirm a clinical diagnosis of FH was investigated in 15 FH-families, consisting of 118 individuals, in whom the presence of Familial Defective Apolipoprotein B-100 (FDB) due to the apoB3500 mutation was excluded. Independent haplotypes were constructed for 71 chromosomes: 15 FH and 56 control haplotypes. A total of 14 different haplotypes was found. In 12 families, clinical diagnosis of FH was confirmed by cosegregation analysis, which makes these RFLPs useful for studying the inheritance of the LDLR gene in 80% of Spanish families with FH. Comparison of haplotypes found in the Spanish sample with those found in Swiss and Norwegians suggests heterogeneity of haplotypes among European populations. 相似文献